Seelos Biosciences

Seelos Biosciences is a clinical-stage biopharmaceutical company headquartered in New York, focused on developing innovative therapies for central nervous system disorders and rare diseases. The company's lead asset, SLS-002, is an intranasal formulation of racemic ketamine designed to rapidly address acute suicidal ideation and behavior in patients with major depressive disorder. Unlike traditional antidepressants that can take weeks to produce effects, SLS-002 targets one of psychiatry's most urgent unmet needs by aiming to deliver fast-acting relief in crisis settings. Seelos leverages the intranasal delivery route to optimize bioavailability and patient accessibility, differentiating its approach from intravenous ketamine-based treatments already on the market. The company's broader pipeline extends across multiple CNS and rare disease indications, reflecting a diversified strategy for long-term growth.

Seelos Biosciences trades publicly on the NASDAQ under the ticker symbol SEEL, giving it access to capital markets to advance its clinical programs. SLS-002 has progressed through clinical development with studies evaluating its safety, tolerability, and efficacy in patients experiencing acute suicidal crises, a population that has historically been underserved by available pharmacological options. The company has worked to generate clinical data supporting both the speed of onset and the therapeutic potential of racemic ketamine delivered intranasally. Seelos continues to build its pipeline through internal development and strategic partnerships, positioning itself to address conditions where existing treatment paradigms fall significantly short. Its public listing has enabled the company to maintain visibility within the broader biopharma investment community while advancing multiple programs simultaneously.

Seelos Biosciences represents an important participant in the growing intersection of neuroscience, mental health innovation, and novel drug delivery technology. The acute suicidal ideation space remains one of the most critical and least addressed areas in all of psychiatry, and companies developing rapid-acting interventions play a meaningful role in reshaping crisis care. By targeting the glutamatergic system through ketamine's mechanism of action, Seelos contributes to a broader scientific movement away from traditional monoamine-based psychiatry toward faster and potentially more effective treatment paradigms. Its work aligns with increasing industry and regulatory attention on mental health, particularly following heightened awareness of suicide as a global public health emergency. As the neurotech and mental health tech sectors continue to attract investment and clinical focus, Seelos Biosciences stands as a specialized player advancing therapies where the clinical and humanitarian stakes are exceptionally high.